Blog · Microbiome

Lactobacillus Crispatus and Vaginal Health: The Evidence

Quick answer

Lactobacillus crispatus vaginal health research shows that L. crispatus often dominates the vaginal bacteria of healthy women, and that one vaginal L. crispatus product lowered BV recurrence in a trial. Those results are vaginal, not oral. FemiCore lists L. crispatus LCr86, with no CFU and no published result.

Written by the FemiCore label benchUpdated October 19, 2026 · 4 min read

Vendor illustration of a petri dish for L. crispatus — Vendor illustration of a culture dish, not a photo or micrograph. It stands for the L. crispatus line on the label.

The microbe

What does Lactobacillus crispatus do in the vagina?

Lactobacillus crispatus is one of several lactobacilli that can dominate the vaginal bacterial community. In a study of 396 women with no symptoms, four of five community types were led by L. crispatus, L. gasseri, L. iners or L. jensenii (Ravel et al. 2011, vaginal microbiome).

The fifth type had few lactobacilli and a more varied mix. It was more common in Black and Hispanic women than in White and Asian women, so that profile is not automatically abnormal (Ravel et al. 2011, vaginal microbiome).

The study describes who carries what. It does not show that adding a strain by mouth changes the community, and it says nothing about leaks or bladder symptoms.

The trial

Did an L. crispatus product help vaginal health in a trial?

One vaginal L. crispatus product did lower the return of bacterial vaginosis (BV) in a trial. Among 228 women first treated with vaginal metronidazole, BV came back within 12 weeks in about 30% on the product, against about 45% on placebo (Cohen et al. 2020, Lactin-V trial).

The product, Lactin-V, is a single strain applied in the vagina after treatment. It is a different thing from a swallowed capsule that holds five lactobacilli.

Evidence for L. crispatus and what it covers
Source	What it studied	Does not show
Community study (Ravel et al. 2011, vaginal microbiome)	Bacteria in 396 healthy women	Any effect of a supplement
Lactin-V trial (Cohen et al. 2020, Lactin-V trial)	BV recurrence, vaginal use	Oral use or bladder effects
LCr86 trial (ClinicalTrials.gov NCT06830122, LCr86)	80 women, oral, 8 weeks	No results posted

By mouth

Can an oral L. crispatus capsule support vaginal health?

Whether an oral L. crispatus capsule supports vaginal health is not established in the sources we hold. The strongest result used a vaginal route, and the oral trial of LCr86 posted no results (ClinicalTrials.gov NCT06830122, LCr86).

That trial gave 10 billion CFU a day by mouth for 8 weeks and scored vaginal bacteria with the Nugent method. We do not know the outcome.

NICE reviewed lactobacillus products for recurrent urinary infections and called the evidence inconclusive (NICE NG112, recurrent UTI). Probiotic effects are also strain-specific (NCCIH, Probiotics).

So a fair reading is hopeful but open. The idea is reasonable, and the proof for this capsule is missing.

On the label

What does FemiCore claim for its L. crispatus line?

FemiCore lists L. crispatus LCr86 first in a 50 mg Probiotic Blend, so by label order it weighs at most 50 mg. The label prints no CFU and no single amount.

The front panel quotes "Microbiome Balance" as a structure-and-function line. It does not name the vagina, and no study of the finished capsule is published.

Vaginal pH and discharge are outside what our sources cover. If you have symptoms such as itching, odor or burning, see a clinician instead of guessing.

Vendor petri-dish illustrations from the sales page, one per label line; not photos of the capsule contents. Weights are label-order ceilings.

FemiCore: from $49 a bottle30 capsules · 2, 3 or 6 bottles · free shipping on 6 · 60-day money-back guarantee

See packs

When to see someone

When is a vaginal or urinary symptom a reason to call a clinician?

Call a clinician when symptoms are new, painful or repeated. Burning on urination, a strong urge, red or cola-colored urine, or pelvic pain can signal a urinary infection, and a fever with back pain can mean the kidneys are involved (Mayo Clinic, UTI).

Blood in the urine always needs a check (MedlinePlus, Blood in urine). A probiotic is not a substitute for that visit, and waiting to see if a capsule helps can delay care.

Next steps

What should you do with this evidence?

Use it to set modest expectations. L. crispatus is a well-studied member of the vaginal community, but no sourced result ties an oral five-strain capsule to bladder or vaginal outcomes.

Keep taking any prescribed medicine, and tell your clinician about any supplement. Speak to them first if you are pregnant, nursing, under 18 or have a medical condition, as the label advises.

The 60-day guarantee badge gives a trial window if you decide to try it. The sales page shows $79, $69 and $49 a bottle on two, three and six bottles.

U.S. stocking partner for FemiCore

Ready to try FemiCore?

Start with a check of your medicines, then pick a pack. Six bottles ship free and cost the least per bottle, and every pack sits inside the 60-day money-back window.

2 bottles$158$79 a bottle 3 bottles$207$69 a bottle Lowest per bottle6 bottles$294$49 a bottle

Order FemiCore Compare packs

Secure checkout
60-day money-back guarantee
Ships from the U.S.

FAQ

L. crispatus questions, answered

Is L. crispatus the same as L. acidophilus?

No. They are separate species of Lactobacillus. FemiCore lists both, as LCr86 and LA88, and effects differ by strain, so a result for one does not carry to the other.

Does a swallowed probiotic reach the vagina?

None of the sources we cite shows that a swallowed capsule changes the vaginal community. Treat the route from gut to vagina as an open question, not a promise.

Is a diverse vaginal community always unhealthy?

No. In the 396-woman study, a diverse type with few lactobacilli was common in some groups and was not automatically abnormal (Ravel et al. 2011, vaginal microbiome).

Why does the label list so many Lactobacillus strains?

A multi-strain blend aims to cover more bases, but no trial shows the five together help. Each strain stands on its own evidence, and four of the five have none.

Should I take a probiotic after antibiotics for BV?

Ask your clinician. The positive trial used a vaginal product after treatment, and oral capsules were not tested in it. Treatment choices belong with them.

Who wrote this

Written and reviewed by

Written byThe FemiCore label benchMyfemicore, U.S. stocking partner for FemiCore

Pages built from the label, the sales page and linked NIH, FDA, FTC, EMA and peer-reviewed sources.

Medically reviewed byDr. Timothy Brown, MD, MScRole: Medical reviewerReview date: October 19, 2026

Last updated October 19, 2026. See our editorial standards and how we check reviews. This website is run by a U.S. stocking partner for FemiCore, not by the manufacturer or the label's distributor. We are paid when you buy through our order links.

Keep reading

More about FemiCore

L. crispatus LCr86

Urinary microbiome basics

How it works